Neurological manifestations of postcovid syndrome

Kamchatnov P.R.; Cheremin R.A.; Skipetrova L.A.; Chugunov A.V.

doi:https://doi.org/10.17116/jnevro20221220317

Close metadata

Recommended articles:

Non-invasive biomarkers for early diagnosis of Alzheimer’s disease in bodily fluids. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):8-16

Arterial hypertension is an oxidative stress, as a pathogenetic target for the treatment of chronic cerebrovascular insufficiency. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):84-90

The effect of Mexidol on the level of neurogenesis markers in acute cerebrovascular accident in the experiment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):107-112

Coronavirus infection as a risk factor in occlusive-stenotic lesions of the brachiocephalic arteries. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):44-52

Comparative study of cognitive impairment in subgroups of bipolar affective disorder types I and II, occurring with and without psychotic symptoms. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):7-11

Diffuse changes in the brain in the acute phase of COVID-19 and after infection. Russian Journal of Archive of Pathology. 2025;(1):5-15

Liver pathology in COVID-19. Russian Journal of Archive of Pathology. 2025;(1):53-59

Results of the All-Russian consensus conference on complications in bariatric surgery. Endoscopic Surgery. 2025;(1):15-24

A clinical case of the aortic rupture after SARS-CoV-2 in the patient with Stickler syndrom. Russian Journal of Preventive Medicine. 2025;(3):103-106

Post-COVID syndrome: organizing COVID-19-associated pneumonia. Clinical case. Journal of Respiratory Medicine. 2025;(1):65-72

Abstract:

The problem of postcovid syndrome (PCS) attracts great interest due to the wide prevalence and variety of clinical manifestations. The main neurological manifestations of PCS are considered. The information about the proposed mechanisms of the formation of PCS is given. The possibility of using the drug Mexidol for the treatment of patients with PCS is discussed.

Keywords:

COVID-19

postcovid syndrome

cognitive impairment

chronic cerebral ischemia

Mexidol

treatment

Authors:

Kamchatnov P.R.

Pirogov Russian National Research Medical University

SPIN RSCI: 9240-6754
Scopus AuthorID: 6602401209
ORCID: 0000-0001-6747-3476

Cheremin R.A.

Center of Speech Pathology and Neurorehabilitation

Skipetrova L.A.

Center for Speech Pathology and Neurorehabilitation

ORCID: 0000-0002-6019-4981

Chugunov A.V.

N.I. Pirogov Russian National Research Medical University

Scopus AuthorID: 7004437778

Received:

15.02.2022

Accepted:

23.02.2022

Close metadata

References:

COVID-19 rapid guideline: managing the long-term effects of COVID-19. NICE guideline [NG188]. Published: 18 December 2020. https://www.nice.org.uk/guidance/ng188
Fauci Introduces New Acronym for Long COVID at White House Briefing—Medscape — Feb 24, 2021. https://www.medscape.com/viewarticle/946419
Clinical case determination of the condition after COVID-19 by the Delphic consensus method on October 6, 2021. WHO reference number: WHO/2019-nCoV/Post_COVID-19_condition/Clinical_case_definition/2021.1. (In Russ.).
Rudroff T, Fietsam AC, Deters JR, et al. Post-COVID-19 Fatigue: Potential Contributing Factors. Brain Sci. 2020;10(12):1012-1020. https://doi.org/10.3390/brainsci10121012
Frontera JA, Lewis A, Melmed K. et al. Prevalence and Predictors of Prolonged Cognitive and Psychological Symptoms Following COVID-19 in the United States. Front Aging Neurosci. 2021;13:690383. https://doi.org/10.3389/fnagi.2021.690383
Ceban F, Ling S, Lui LMW, et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav Immun. 2021;101:93-135. https://doi.org/10.1016/j.bbi.2021.12.020
Hopkins C, Surda P, Whitehead E, Kumar BN. Early recovery following new onset anosmia during the COVID-19 pandemic — an observational cohort study. J Otolaryngol Head Neck Surg. 2020;49(1):26. https://doi.org/10.1186/s40463-020-00423-8
Jason LA, Islam M, Conroy K, et al. COVID-19 Symptoms Over Time: Comparing Long-Haulers to ME/CFS. Fatigue. 2021;9(2):59-68. https://doi.org/10.1080/21641846.2021.1922140
Taboada M, Cariñena A, Moreno E, et al. Post-COVID-19 functional status six-months after hospitalization. J Infect. 2021;82(4):31-33. https://doi.org/10.1016/j.jinf.2020.12.022
Lam MHB, Wing YK, Yu MWM, et al. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. Arch Intern Med. 2009;169(22):2142-2147. https://doi.org/10.1001/archinternmed.2009.384
Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7(7):611-627. https://doi.org/10.1016/S2215-0366(20)30203-0
Hoffman LA, Vilensky JA. Encephalitis lethargica: 100 years after the epidemic. Brain. 2017;140(8):2246-2251. https://doi.org/10.1093/brain/awx177
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062.
Writing Committee for the COMEBAC Study Group, Morin L, Savale L, Pham T, et al. Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19. JAMA. 2021;325(15):1525-1534. https://doi.org/10.1001/jama.2021.3331
Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626-631. https://doi.org/10.1038/s41591-021-01292-y
Wyrwich KW, Yu H, Sato R, Powers JH. Observational longitudinal study of symptom burden and time for recovery from community-acquired pneumonia reported by older adults surveyed nationwide using the CAP Burden of Illness Questionnaire. Patient Relat Outcome Meas. 2015;6:215-23. https://doi.org/10.2147/PROM.S85779
Evans RA, McAuley H, Harrison EM, et al. PHOSP-COVID Collaborative Group. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir Med. 2021;9(11):1275-1287. https://doi.org/10.1016/S2213-2600(21)00383-0
Office for National Statistics Updated estimates of the prevalence of long COVID symptoms. January, 2021. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/adhocs/12788updatedestimatesoftheprevalenceoflongcovidsymptoms [Ref list]
Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-436. https://doi.org/10.1038/s41586-020-2521-4
Ravi K. Ethnic disparities in COVID-19 mortality: are comorbidities to blame? Lancet. 2020;396(10243):22-24. https://doi.org/10.1016/S0140-6736(20)31423-9
Heckenberg RA, Eddy P, Kent S, Wright BJ. Do workplace-based mindfulness meditation programs improve physiological indices of stress? A systematic review and meta-analysis. J Psychosom Res. 2018;114:62-71. https://doi.org/10.1016/j.jpsychores.2018.09.010
Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC Neurol. 2011;11:37-41. https://doi.org/10.1186/1471-2377-11-37
Voss JG. Predictors and correlates of fatigue in HIV/AIDS. J Pain Symptom Manage. 2005;29:173-184. https://doi.org/10.1016/j.jpainsymman.2004.05.006
Svenningsen H, Langhorn L, Ågård AS, et al. Post-ICU symptoms, consequences, and follow-up: an integrative review. Nurs Crit Care 2017;22:212-220. https://doi.org/10.1111/nicc.12165
Taquet M, Geddes JR, Husain M, et al. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8(5):416-427. https://doi.org/10.1016/S2215-0366(21)00084-5
McIntyre RS, Anderson N, Baune BT, et al. Expert Consensus on Screening and Assessment of Cognition in Psychiatry. CNS Spectr. 2019;24(1):154-162. https://doi.org/10.1017/S1092852918001189
Miskowiak KW, Johnsen S, Sattler SM, et al. Cognitive impairments four months after COVID-19 hospital discharge: Pattern, severity and association with illness variables. Eur Neuropsychopharmacol. 2021;46:39-48. https://doi.org/10.1016/j.euroneuro.2021.03.019
Hugon J, Msika EF, Queneau M, et al. Long COVID: cognitive complaints (brain fog) and dysfunction of the cingulate cortex. Journal of Neurology. 2022;269:44-46. https://doi.org/10.1007/s00415-021-10655-x
Lichenstein SD, Verstynen T, Forbes EE. Adolescent brain development and depression: a case for the importance of connectivity of the anterior cingulate cortex. Neurosci Biobehav Rev. 2016;70:271-287.
Su L, Cai Y, Xu Y, et al. Cerebral metabolism in major depressive disorder: a voxel-based metaanalysis of positron emission tomography studies. BMC Psychiatr. 2014;14:321-330.
Coutinho AMN, Porto FHG, Zampieri PF, et al. Analysis of the posterior cingulate cortex with [18F] FDG-PET and Naa/mI in mild cognitive impairment and Alzheimer’s disease: correlations and differences between the two methods. Dement Neuropsychol. 2015;9:385-393.
Guedj E, Campion JY, Dudouet P, et al. 18F-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol Imaging. 2021;48(9):2823-2833. https://doi.org/10.1007/s00259-021-05215-4
Kanberg N, Simrén J, Edén A, et al. Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. EBioMedicine. 2021;70:103512. https://doi.org/10.1016/j.ebiom.2021.103512
Edén A, Simrén J, Price RW, et al. Neurochemical biomarkers to study CNS effects of COVID-19: A narrative review and synthesis. J Neurochem. 2021;159(1):61-77. https://doi.org/10.1111/jnc.15459
Meppie, E, Peiffer‐Smadja N, Maury A, et al. Neurological manifestations associated with COVID‐19: A multicentric registry. Clinical Microbiology & Infection. 2021;27:458-466.
Virhammar J, Nääs A, Fällmar D, et al. Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity. Eur J Neurol. 2021;28(10):3324-3331. https://doi.org/10.1111/ene.14703
Schwabenland M, Salie H, Tanevski J, et al. Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions. Immunity. 2021;54:1594-1610. https://doi.org/10.1016/j.immuni.2021.06.002
Zakharov VV. Postcovid syndrome through the eyes of a neurologist. Behavioral Neurology. 2021;2:14-22. (In Russ.). https://doi.org/10.46393/2712-9675_2021_2_14_22
Kamchatnov PR, Solov’eva EYu, Khasanova DR, Fateeva VV. Asthenic and cognitive disorders after the COVID-19 infection. Russian Medical Inquiry. 2021;5(10):636-641. (In Russ.). https://doi.org/10.32364/2587-6821-2021-5-10-636-641
Dani M, Dirksen A, Taraborrelli P, et al. Autonomic dysfunction in ‘long COVID’: rationale, physiology and management strategies. Clin Med (Lond). 2021;21(1):63-67. https://doi.org/10.7861/clinmed.2020-0896
Goldstein DS. The extended autonomic system, dyshomeostasis, and COVID-19. Clin Auton Res. 2020;30(4):299-315. https://doi.org/10.1007/s10286-020-00714-0
Stefano GB, Ptacek R, Ptackova H, et al. Selective Neuronal Mitochondrial Targeting in SARS-CoV-2 Infection Affects Cognitive Processes to Induce ‘Brain Fog’ and Results in Behavioral Changes that Favor Viral Survival. Med Sci Monit. 2021;27:e930886. https://doi.org/10.12659/MSM.930886
Goldstein DS. The possible association between COVID-19 and postural tachycardia syndrome. Heart Rhythm. 2021;18(4):508-509. https://doi.org/10.1016/j.hrthm.2020.12.007
Quadt L, Critchley H, Nagai Y. Cognition, emotion, and the central autonomic network. Published: January 28, 2022. https://doi.org/10.1016/j.autneu.2022.102948
Novak CB, Scheeler VM, Aucott JN. Lyme Disease in the Era of COVID-19: A Delayed Diagnosis and Risk for Complications. Case Rep Infect Dis. 2021;2021:6699536. https://doi.org/10.1155/2021/6699536
Chertow DS. Understanding long-term effects of Ebola virus disease. Nat Med. 2019;25(5):714-715. https://doi.org/10.1038/s41591-019-0444-0
Almutairi MM, Sivandzade F, Albekairi TH, et al. Neuroinflammation and Its Impact on the Pathogenesis of COVID-19. Front Med (Lausanne). 2021;8:745789. https://doi.org/10.3389/fmed.2021.745789
Najjar S, Najjar A, Chong DJ, et al. Central nervous system complications associated with SARS-CoV-2 infection: integrative concepts of pathophysiology and case reports. J Neuroinflammation. 2020;17(1):231. https://doi.org/10.1186/s12974-020-01896-0
Jarrott B, Head R, Pringle KG, et al. «LONG COVID»-A hypothesis for understanding the biological basis and pharmacological treatment strategy. Pharmacol Res Perspect. 2022;10(1):e00911. https://doi.org/10.1002/prp2.911
Murta V, Villarreal A, Ramos AJ. Severe Acute Respiratory Syndrome Coronavirus 2 Impact on the Central Nervous System: Are Astrocytes and Microglia Main Players or Merely Bystanders? ASN Neuro. 2020;12:1759091420954960. https://doi.org/10.1177/1759091420954960
Stefano GB, Büttiker P, Weissenberger S, et al. Editorial: The Pathogenesis of Long-Term Neuropsychiatric COVID-19 and the Role of Microglia, Mitochondria, and Persistent Neuroinflammation: A Hypothesis. Med Sci Monit. 2021;27:e933015. https://doi.org/10.12659/MSM.933015
Rimes KA, Chalder T. Treatments for chronic fatigue syndrome. Occup Med (Lond). 2005;55:32-39. https://doi.org/10.1093/occmed/kqi015
NICE cautions against using graded exercise therapy for patients recovering from COVID-19. BMJ. 2020;370:m2912. https://doi.org/10.1136/bmj.m2912
National Institute for Health and Care Excellence. Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy): diagnosis and management. Clinical guideline [CG53]. 22 Aug 2007. https://www.nice.org.uk/Guidance/CG53.
National Institute for Health and Care Excellence. Statement about graded exercise therapy in the context of COVID-19. Jul 2020. https://www.nice.org.uk/guidance/gid-ng10091/documents/interim-findings-2
Nurek M, Rayner C, Freyer A, et al. Recommendations for the recognition, diagnosis, and management of long COVID: a Delphi study. Br J Gen Pract. 2021. https://doi.org/10.3399/BJGP.2021.0265
Belova AN, Bogdanov EI, Voznyuk IA, et al. Therapy of moderate cognitive impairment in the early recovery period of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2021;121(5):1-7. (In Russ.). https://doi.org/10.17116/jnevro202112105133
Parfenov VA, Kamchatnov PR, Khasanova DR. et al. The randomized clinical trial results of the anxiety treatment in patients with somatoform dysfunction and neurotic disorders. Sci Rep. 2021;1:24282. https://doi.org/10.1038/s41598-021-03727-5
Voronina TA. Antioxidants/antihypoxants: the missing puzzle piece in effective pathogenetic therapy for COVID-19. Infekc Bolezni (Infectious diseases). 2020;18(2):97-102. (In Russ.). https://doi.org/10.20953/1729-9225-2020-2-97-102
Schulkin AV, Filimonova AA. Role of free radical oxidation, hypoxia and their correction in COVID-19 pathogenesis. Therapy. 2020;5:187-194. (In Russ). https://doi.org/10.18565/therapy.2020.5.187-194
Zhuravleva MV, Prokofiev AB, Serebrova SYu. et al. Efficacy and safety of ethylmethylhydroxypyridine succinate in patients with chronic cerebral ischemia. Journal of Neurology and Psychiatry named after S.S. Korsakov. 2020;120(6):119-124. (In Russ.). https://doi.org/10.17116/jnevro2020120061119
Chukanova EI, Chukanova AS. Efficacy and safety of the drug Mexidol FORTE 250 in the framework of sequential therapy in patients with chronic cerebral ischemia. Journal of Neurology and Psychiatry named after S.S. Korsakov. 2019;119(9):39-45. (In Russ.). https://doi.org/10.17116/jnevro201911909139
Duma SN. Possibilities of antioxidant therapy for asthenia and cognitive deficit in elderly patients with chronic brain ischemia. Terapevticheskii Arkhiv. 2013;85(12):100-105. (In Russ.).
Shchepankevich LA, Nikolaev YuA, Taneeva EV, et al. The efficacy and safety study of Mexidol and Mexidol FORTE 250 in patients with chronic cerebral ischemia. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2021;121(10):32-37. (In Russ.). https://doi.org/10.17116/jnevro202112110132
Fedin AI, Zakharov VV, Tanashyan MM, et al. Results of an international multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO). Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2021;121(11):7-16. (In Russ.). https://doi.org/10.17116/jnevro20211211117
Shavarova EK, Cazakhmedov ER, Alekseeva MV, et al. Role of antioxidant therapy in patients with moderate and severe COVID-19. Infekc Bolezni (Infectious Diseases). 2021;19(1):159-164. (In Russ.). https://doi.org/10.20953/1729-9225-2021-1-159-164
Kovalchuk VV, Ershova II, Molodovskaya NV. Possibilities of improving the effectiveness of therapy in patients with chronic cerebral ischemia against the background of COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2021;121(3 vyp 2):60-66. (In Russ.). https://doi.org/10.17116/jnevro202112103260
Methodological recommendations «Features of the course of Long-COVID infection. Therapeutic and rehabilitation measures: Ap. to the J «Therapy». 2022:1 (In Russ.).